Pharmacokinetics-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612

被引：0
|
作者：
Birnberg, T. [1 ]
Adar, L. [1 ]
Poewe, W. [2 ]
Nyholm, D. [3 ]
Bjornsson, M. [4 ]
Karlsson, M. [4 ]
机构：
[1] NeuroDerm, Rehovot, Israel
[2] Med Univ Innsbruck, Innsbruck, Austria
[3] Uppsala Univ, Uppsala, Sweden
[4] Pharmetheus, Uppsala, Sweden
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-363
引用
收藏
页码：608 / 608
页数：1
相关论文
共 50 条
  • [31] Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612
    Poewe, W.
    Ellenbogen, A.
    Lopes, N.
    Pahwa, R.
    MOVEMENT DISORDERS, 2024, 39 : S306 - S306
  • [32] Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612
    Pahwa, Rajesh
    Ellenbogen, Aaron
    Lopes, Nelson
    Poewe, Werner
    ANNALS OF NEUROLOGY, 2024, 96 : S220 - S220
  • [33] CONTINUOUS SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION WITH ND0612 FOR PARKINSON'S DISEASE: THREE-YEAR DATA FROM THE OPEN-LABEL BEYOND STUDY
    Stocchi, F.
    Poewe, W.
    Ellenbogen, A.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [34] Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612
    Isaacson, S.
    Rascol, O.
    Sarva, H.
    Hauser, R.
    Stocchi, F.
    Lopes, N.
    Salin, L.
    Pereira, J.
    Giladi, N.
    MOVEMENT DISORDERS, 2024, 39 : S313 - S313
  • [35] Pharmacokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson's disease (PD) patients with motor fluctuations: results of a phase IIa dose finding study
    Giladi, N.
    Caraco, Y.
    Gurevich, T.
    Djaldetti, R.
    Cohen, Y.
    Yacobi-Zeevi, O.
    Oren, S.
    Kieburtz, K.
    Olanow, C. W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 66 - 66
  • [36] Identification of the optimal carbidopa concentration in subcutaneously administered ND0612
    Adar, L.
    Minei, T. Rachmilewitz
    Oren, S.
    MOVEMENT DISORDERS, 2017, 32
  • [37] Pharmacokinetic profile of ND0612L (levodopa/carbidopa for subcutaneous infusion) in patients with moderate to severe Parkinson's disease
    Giladi, N.
    Caraco, Y.
    Gurevich, T.
    Djaldetti, R.
    Cohen, Y.
    Yacobi-Zeevi, O.
    Oren, S.
    MOVEMENT DISORDERS, 2015, 30 : S87 - S88
  • [38] BOUNDLESS: AN ACTIVE-CONTROLLED, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY TRIAL OF CONTINUOUS SUBCUTANEOUS INFUSION OF LEVODOPA/CARBIDOPA WITH ND0612 IN PATIENTS WITH PARKINSON'S DISEASE
    Rascol, O.
    Poewe, W.
    Stocchi, F.
    Yardeni, T.
    Barak, S. Leibman
    Adar, L.
    Rosenfeld, O.
    Olanow, C. W.
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : E53 - E53
  • [39] Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study
    Ellenbogen, Aaron L.
    Poewe, Werner
    Espay, Alberto J.
    Simuni, Tanya
    Gurevich, Tanya
    Yardeni, Tami
    Lopes, Nelson
    Sasson, Nissim
    Case, Ryan
    Stocchi, Fabrizio
    BeyoND Study Grp
    PARKINSONISM & RELATED DISORDERS, 2025, 132
  • [40] Quality of Life with 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612): PDQ-39 Results from a Phase 3 Randomized Active-Controlled Study
    Sarva, H.
    Tagliati, M.
    Poewe, W.
    Stocchi, F.
    Rascol, O.
    Yardeni, T.
    Lopes, N.
    Pereira, J.
    Espay, A.
    MOVEMENT DISORDERS, 2024, 39 : S298 - S298
12345